Hello, everyone, and how are you today? We are doing fine, thank you, despite the chilly wintry air enveloping the Pharmalot campus. The short people have left for their respective destinations and the official mascots are snoozing away. Moments like this call for a few cups of stimulation, of course, and we are indulging by toggling between peppermint mocha and butter pecan. Feel free to join us. Meanwhile, here are a few tidbits to help you along. We hope your day is productive and meaningful. And, as always, do keep in touch …

As former Insys Therapeutics (INSY) executives face trials for bribing doctors to boost sales of the Subsys opioid painkiller, the new managers at the company are trying to sell the pain drug to a corporate buyer to raise money, Bloomberg News tells us. And they hope to use the proceeds to pivot out of the opioid business into something slightly less controversial — cannabis-derived drugs. “This pivot may be forced, but CBD and opioid dependence are hot spaces with a lot of interest from investors,” says Curt Wanek, a pharmaceutical equity analyst for Bloomberg Intelligence.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy